Results from the 2nd Scientific Workshop of the ECCO (I): Impact of mucosal healing on the course of inflammatory bowel disease
Laurent Peyrin-Biroulet,Marc Ferrante,Fernando Magro,Simon Campbell,Denis Franchimont,Herma H. Fidder,Hans Strid,Sandro Ardizzone,Gigi Veereman-Wauters,Jean Baptiste Chevaux,Mathieu Allez,Silvio Danese,Andreas Sturm +12 more
Reads0
Chats0
TLDR
Accumulating evidence indicates that mucosal healing may change the natural course of the disease by decreasing the need for surgery and reducing hospitalization rates in both ulcerative colitis and Crohn's disease.About:
This article is published in Journal of Crohn's and Colitis.The article was published on 2011-10-01 and is currently open access. It has received 299 citations till now. The article focuses on the topics: Inflammatory bowel disease & Crohn's disease.read more
Citations
More filters
Journal ArticleDOI
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders.
Fernando Magro,Paolo Gionchetti,Rami Eliakim,Sandro Ardizzone,Alessandro Armuzzi,Manuel Barreiro-de Acosta,Johan Burisch,Krisztina Gecse,Ailsa Hart,Pieter Hindryckx,Cord Langner,Jimmy K. Limdi,Gianluca Pellino,Edyta Zagórowicz,Tim Raine,Marcus Harbord,Florian Rieder +16 more
TL;DR: This research presents a meta-analyses of Gastroenterology and Hepatology at the cellular and molecular level, which shows clear trends in the development of immune-oncology-metabolical pathways towards “clinically checkpoints”.
Journal ArticleDOI
European evidence based consensus for endoscopy in inflammatory bowel disease
Vito Annese,Marco Daperno,Matthew D. Rutter,Matthew D. Rutter,Aurelien Amiot,Peter Bossuyt,James E. East,Marc Ferrante,Martin Götz,Konstantinos Katsanos,Ralf Kießlich,Ingrid Ordás,Alessandro Repici,Bruno Rosa,Shaji Sebastian,Torsten Kucharzik,Rami Eliakim +16 more
TL;DR: The development of guidelines is an expensive and time-consuming process, but this Consensus may help to avoid duplication of effort in the future and identify issues where the evidence is lacking and controlled studies are awaited.
Journal ArticleDOI
Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial
Laurent Peyrin-Biroulet,Walter Reinisch,Jean-Frederic Colombel,Gerassimos J. Mantzaris,Asher Kornbluth,Robert H. Diamond,Paul Rutgeerts,Linda K Tang,Freddy Cornillie,William J. Sandborn +9 more
TL;DR: Half the patients under azathioprine and/or infliximab in clinical remission have endoscopic and/ or CRP evidence of residual active CD, whereas other patients with endoscopicand CRP normalisation have persistent clinical symptoms.
Journal ArticleDOI
Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up
Robert V Bryant,Daniel Burger,Joseph Delo,Alissa Walsh,S Thomas,Axel von Herbay,O C Buchel,Lydia White,Oliver Brain,Satish Keshav,Bryan F. Warren,Simon Travis +11 more
TL;DR: Histological remission is a target distinct from endoscopic mucosal healing in UC and better predicts lower rates of corticosteroid use and acute severe colitis requiring hospitalisation, over a median of 6 years of follow-up.
References
More filters
Journal ArticleDOI
Infliximab for induction and maintenance therapy for ulcerative colitis.
Paul Rutgeerts,William J. Sandborn,Brian G. Feagan,Walter Reinisch,Allan Olson,Jewel Johanns,Suzanne Travers,Daniel Rachmilewitz,Stephen B. Hanauer,Gary R. Lichtenstein,Willem J.S. de Villiers,Daniel H. Present,Bruce E. Sands,Jean-Frederic Colombel +13 more
TL;DR: Patients with moderate-to-severe active ulcerative colitis treated with infliximab at weeks 0, 2, and 6 and every eight weeks thereafter were more likely to have a clinical response at weeks 8, 30, and 54 than were those receiving placebo.
Journal ArticleDOI
Predictability of the postoperative course of Crohn's disease
TL;DR: The early postoperative lesions in the neoterminal ileum seem to be a suitable model to study the pathogenesis of Crohn's disease and also to evaluate new therapeutic modalities, either to prevent development of these early lesions or to treat progressive recurrence.
Journal ArticleDOI
Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis
Matthew D. Rutter,Brian Saunders,Kay H. Wilkinson,Steve Rumbles,Gillian Schofield,Michael A. Kamm,Christopher S. Williams,Ashley B. Price,Ian C. Talbot,Alastair Forbes +9 more
TL;DR: In long-standing extensive ulcerative colitis, the severity of colonic inflammation is an important determinant of the risk of colorectal neoplasia and endoscopic and histological grading of inflammation could allow better risk stratification for surveillance programs.
Journal ArticleDOI
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial
Geert R. D'Haens,Filip Baert,Gert Van Assche,Philip Caenepeel,Philippe Vergauwe,Hans Tuynman,Martine De Vos,Sander J. H. van Deventer,Larry Stitt,Allan Donner,Allan Donner,Severine Vermeire,Frank J. Van de Mierop,Jean-Charles R Coche,Janneke van der Woude,Thomas Ochsenkühn,Ad A. van Bodegraven,Philippe Van Hootegem,Guy Lambrecht,Fazia Mana,Paul Rutgeerts,Brian G. Feagan,Brian G. Feagan,Daniel W. Hommes +23 more
TL;DR: Combined immunosuppression was more effective than conventional management for induction of remission and reduction of corticosteroid use in patients who had been recently diagnosed with Crohn's disease.
Journal ArticleDOI
Mucosal Healing in Inflammatory Bowel Disease: Results From a Norwegian Population-Based Cohort
TL;DR: The present results give further strength to the use of mucosal healing as a clinical indicator and treatment goal in inflammatory bowel disease.